BCIQ Profiles

Company Profile ReportTarget Profile Report
0812 Bluejay ECP
BioCentury & Getty Images

Emerging Company Profile

Bluejay: combining HBV therapies to reach a functional cure

Emerging Company Profile: Led by Keting Chu, Bluejay is advancing HBV assets in-licensed from Novartis

Led by Keting Chu, Bluejay is advancing a trio of HBV assets in-licensed from Novartis after the pharma exited antiviral research. 

Aug 12, 2021 | 8:53 PM GMT

Bluejay is applying a combination of therapies in-licensed from Novartis with an aim to cure chronic HBV by reducing viral surface antigen in both the liver and blood.

Founder,

Read the full 859 word article

How to gain access

Continue reading with a
two-week free trial.